Garner Thomas has filed 7 insider transactions across 2 companies since October 2023.
Most recent transaction: a grant/award of 28493 shares of ACADIA PHARMACEUTICALS INC ($ACAD) on March 06, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 6, 2026 | ACADIA PHARMACEUTICALS INC | $ACAD | Garner Thomas | EVP, Chief Commercial Officer | A | Restricted Stock Units | 28493 | $0.00 | 28,493.0000 | 170,650,000 | 9999.99% | 0.02% |
| March 6, 2026 | ACADIA PHARMACEUTICALS INC | $ACAD | Garner Thomas | EVP, Chief Commercial Officer | A | Stock Option (Right to Buy) | 97947 | $0.00 | 97,947.0000 | 170,650,000 | 9999.99% | 0.06% |
| Dec. 9, 2024 | ACADIA PHARMACEUTICALS INC | $ACAD | Garner Thomas | EVP, Chief Commercial Officer | A | Restricted Stock Units | 45372 | $0.00 | 45,372.0000 | 166,178,000 | 9999.99% | 0.03% |
| Dec. 9, 2024 | ACADIA PHARMACEUTICALS INC | $ACAD | Garner Thomas | EVP, Chief Commercial Officer | A | Stock Option (Right to Buy) | 235849 | $0.00 | 235,849.0000 | 166,178,000 | 9999.99% | 0.14% |
| Feb. 8, 2024 | LEXICON PHARMACEUTICALS, INC. | $LXRX | Garner Thomas | SVP, Chief Commercial Officer | A | Restricted Stock Units | 227130 | $0.00 | 227,130.0000 | 0 | 9999.99% | 0.00% |
| Feb. 8, 2024 | LEXICON PHARMACEUTICALS, INC. | $LXRX | Garner Thomas | SVP, Chief Commercial Officer | A | Stock Option (Right to Buy) | 227130 | $0.00 | 227,130.0000 | 0 | 9999.99% | 0.00% |
| Oct. 9, 2023 | LEXICON PHARMACEUTICALS, INC. | $LXRX | Garner Thomas | SVP, Chief Commercial Officer | A | Stock Option (Right to Buy) | 248923 | $0.00 | 248,923.0000 | 0 | 9999.99% | 0.00% |